You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

JEMPERLI ▼ (dostarlimab) logo

Product menu

JEMPERLI patient at window
Dosing JEMPERLI▼

JEMPERLI + CP Dosing Established in the RUBY Trial

Deliver a Proven Combination Up Front, Then Continue With Single-Agent Immunotherapy1

Recommended Dosage of JEMPERLI in Primary Advanced or Recurrent Endometrial Cancer1

Dosing schedule for JEMPERLI in combination with carboplatin and paclitaxel Dosing schedule for JEMPERLI in combination with carboplatin and paclitaxel

*Administer JEMPERLI prior to carboplatin and paclitaxel on the same day.1

The Q3W dosing schedule allows for more frequent patient monitoring during the 6-cycle treatment initiation phase.1

The number of infusion visits is reduced over the long term during the Q6W monotherapy phase.1

  • Additional monitoring may be required at clinical discretion1

Full receptor occupancy as measured by both the direct PD-1 binding and interleukin 2 production functional assay was maintained throughout the dosing interval at the recommended therapeutic dosing regimen.1

CP=carboplatin + paclitaxel; dMMR=mismatch repair deficient; MSI-H=microsatellite instability-high; PD-1=programmed death receptor 1; Q3W=every 3 weeks; Q6W=every 6 weeks.

JEMPERLI Monotherapy Dosing Established in the GARNET Trial

The JEMPERLI Dosing Regimen Reduces the Frequency of Dosing Visits for Your Patients After Transitioning From Q3W to Q6W Dosing1*

Recommended Dosage of JEMPERLI Monotherapy in Post-Platinum dMMR/MSI-H Recurrent or Advanced Endometrial Cancer

Dosing schedule for JEMPERLI as a single agent Dosing schedule for JEMPERLI as a single agent

*Additional monitoring may be required per clinical discretion.1

JEMPERLI Is Available in Fixed-Dose Vials for Simple Dosing1

  • For the 500-mg dose, withdraw 10 mL of JEMPERLI from a vial and transfer into an intravenous bag containing:
    -Sodium chloride 9 mg/mL (0.9%) solution for injection
    or
    -Glucose 50 mg/mL (5%) solution for injection
  • For the 1000-mg dose, withdraw 10 mL of JEMPERLI from each of two vials (withdraw 20 mL total) and transfer into an intravenous bag containing:
    -Sodium chloride 9 mg/mL (0.9%) solution for injection
    or
    -Glucose 50 mg/mL (5%) solution for injection
  • The final concentration of the diluted solution should be between 2 mg/mL and 10 mg/mL. The total volume of the infusion solution must not exceed 250 mL. This may require withdrawing a volume of diluent from the intravenous bag prior to adding a volume of JEMPERLI into the intravenous bag.
  • Each dose of JEMPERLI is administered as a 30-minute intravenous infusion
  • A 0.2 or 0.22 micron in-line polyethersulfone (PES) filter must be used during administration of JEMPERLI.

 

Recommended Dose Modifications for JEMPERLI1

Management of adverse reactions*

Dose reduction is not recommended. Dosing delay or discontinuation may be required based on individual safety and tolerability. All adverse reactions are immune-related unless otherwise noted.

*Severity based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.1
†For patients with liver metastases who begin treatment with a Grade 2 increase of AST or ALT, if AST or ALT increases by ≥50% relative to baseline and lasts for at least 1 week, then treatment should be discontinued.1


ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal.

Find Out More

RUBY Trial Results

See RUBY Data

Jemperli Mode of Action

See MoA

JEMPERLI Resources and Support

See Resources and Support

JEMPERLI Is Indicated

  • JEMPERLI is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.
  • JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.

Reference

  1. Jemperli (dostarlimab) Summary of product characteristics January 2025 https://www.medicines.ie/ Last accessed April 2025.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie.
Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com/.

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

© 2025 - 2026 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

PM-IE-DST-WCNT-250001 | March 2025